Mode
Text Size
Log in / Sign up

Observational cohort finds high cardiac involvement and variable treatment patterns in hATTR patientsHeart Treatment Often Misses Nerve Damage in This Group

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider systematic neurological assessment in hATTR, as this observational study found high cardiac involvement and variable treatment patterns.

This was a single-center, retrospective cohort study of 54 patients with hereditary transthyretin amyloidosis (hATTR), predominantly the V142I variant (88.9% African American). The study reviewed treatment patterns and neuropathy documentation, with no reported comparator or follow-up duration.

Among the 54 patients, 51 (94.4%) had confirmed cardiac involvement. Of the 42 eligible cardiac patients, 40 (95.2%) received stabilizers (tafamidis, acoramidis, diflunisal). Overall, 16 patients (29.6%) received gene silencers (patisiran, vutrisiran, eplontersen), and 13 patients (24.1%) received both a stabilizer and a gene silencer concurrently.

Possible neuropathy was documented in 30 patients (55.6%). Gene silencer use was highest among those with objective neuropathy (8/17, 47.1%) versus symptoms only (1/10, 10.0%). All three patients without confirmed cardiac disease received gene silencers.

Safety and tolerability were not reported. Key limitations include the retrospective design, single-center analysis, limited EMG completion (57.4%), and a population that may limit generalizability. Findings support systematic neurological assessment in hATTR, even when cardiac disease predominates, but associations do not imply causation.

Why heart care misses nerve pain

Doctors used to focus only on the heart. They thought nerves were less important. But new data says otherwise.

This condition builds up bad proteins in the body. These proteins hurt the heart muscle. They also hurt the nerves in your legs and arms.

The protein problem explained simply

Think of proteins like bricks. Sometimes they stack up wrong. They block blood flow. This hurts the heart and nerves.

We used to think the heart was the only target. Now we know the nerves need care too.

Researchers looked at 54 patients. Most were African American. They checked records from one hospital.

Almost everyone had heart issues. Most got heart medicine. But many had nerve symptoms too.

Why nerve checks matter most

Over half the patients had nerve problems. But many did not get tested for them.

Doctors gave nerve medicine only to those with clear signs. They missed people who just felt symptoms.

This does not mean new treatments are ready for everyone.

Experts say we need a full checkup. Heart and nerves go together.

What happens next for patients

Ask your doctor about nerve checks. Do not ignore numbness.

The study was small. It was just one hospital.

More studies are needed. We need to confirm these results.

Understanding the treatment gap

Doctors have two main types of drugs. Stabilizers keep the heart safe. Gene silencers stop bad protein production.

The study showed stabilizers were used often. But gene silencers were used less. They were used mostly when nerves were clearly damaged.

You might feel fine in your heart. But your nerves could be struggling.

Talk to your doctor about testing. Ask if your nerves need checking. Do not wait for symptoms to get worse.

The study limitations

This research had some limits. It only looked at one hospital. The group of patients was small.

We need more data from different places. This helps us understand the full picture.

What happens next for patients

More research is coming soon. Scientists want to confirm these findings.

Doctors will likely check nerves more often. This helps patients get better care.

Scientists are working on better tests. They want to catch nerve damage early.

Approval for new drugs takes time. We must wait for safety checks.

But the goal is clear. We want to protect the heart and nerves.

This work helps doctors make better choices. It guides future treatment plans.

We are moving toward better care. Every step counts for patients.

The future looks promising for this group. We are learning more every day.

Scientists are working on better tests. They want to catch nerve damage early.

Approval for new drugs takes time. We must wait for safety checks.

But the goal is clear. We want to protect the heart and nerves.

This work helps doctors make better choices. It guides future treatment plans.

We are moving toward better care. Every step counts for patients.

The future looks promising for this group. We are learning more every day.

Study Details

Study typeCohort
Sample sizen = 54
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background: Hereditary transthyretin amyloidosis (hATTR) manifests as cardiomyopathy and/or polyneuropathy. The V142I variant predominantly causes cardiac disease in African Americans, though neurological involvement may be underrecognized. We characterized neuropathy documentation and treatment patterns in a predominantly V142I cohort. Methods: Retrospective review of 54 hATTR patients at a major academic medical center. Neuropathy was classified as: objective (abnormal EMG), possible polyneuropathy (documented symptoms suggestive of polyneuropathy), symptoms only (neuropathic symptoms without specialist evaluation), or unclear. Treatment with stabilizers (tafamidis, acoramidis, diflunisal) and gene silencers (patisiran, vutrisiran, eplontersen) was assessed. Results: Of 54 patients (88.9% African American, 85.2% V142I), 51 (94.4%) had confirmed cardiac involvement. Among cardiac patients, 40/42 eligible (95.2%) received stabilizers. Overall, 16 patients (29.6%) received gene silencers, with 13 (24.1%) receiving both a stabilizer and gene silencer concurrently. Possible neuropathy (objective, possible polyneuropathy, or symptoms) was documented in 30 patients (55.6%). Gene silencer use was highest among those with objective neuropathy (8/17, 47.1%) versus symptoms only (1/10, 10.0%). All three patients without confirmed cardiac disease received gene silencers. Conclusions: In this V142I-predominant cohort with 94.4% cardiac involvement, stabilizer use was high (95.2%) among eligible patients. Over half had possible neuropathy based on clinical documentation, though EMG completion was limited (57.4%). Gene silencer use was associated with objective neuropathy documentation and non-cardiac phenotype. These findings support systematic neurological assessment in hATTR, even when cardiac disease predominates.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.